Pharmacogenetics in pediatrics. Implications for practice.
about
Use of di(2-ethylhexyl) phthalate-containing medical products and urinary levels of mono(2-ethylhexyl) phthalate in neonatal intensive care unit infantsPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseGene expression profiling of DEHP-treated cardiomyocytes reveals potential causes of phthalate arrhythmogenicityThe adverse cardiac effects of Di(2-ethylhexyl)phthalate and Bisphenol AClinical pharmacology in the adolescent oncology patient.Absence of effect of stimulants on the phamacokinetics of desipramine in children.Acetaminophen intoxication during treatment: what you don't know can hurt you.Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Toxicogenomic Screening of Replacements for Di(2-Ethylhexyl) Phthalate (DEHP) Using the Immortalized TM4 Sertoli Cell LineFunctional interactions between P-glycoprotein and CYP3A in drug metabolism.Exposure to phthalates in neonatal intensive care unit infants: urinary concentrations of monoesters and oxidative metabolitesSafety of the newer antihypertensive agents in children.Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndromeDifferences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.Unusual presentation of iatrogenic phenytoin toxicity in a newborn.Assessing secondhand smoke using biological markersHormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.ATSDR evaluation of health effects of benzene and relevance to public health.Acrolein health effects.Hidden Toxicity in Neonatal Intensive Care Units: Phthalate Exposure in Very Low Birth Weight InfantsOntogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies.Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.The coming of age of a young subspecialty: paediatric hepatology.Basic and translational research in neonatal pharmacology.Pharmacokinetics of metoclopramide in neonates.Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates.Omeprazole disposition in children following single-dose administration.Pharmacogenomic testing in child and adolescent psychiatry: An evidence-based review.Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double-blind trial in Swedish children aged 1.5-3.5 years.
P2860
Q24815609-D76CB7DC-5906-4F47-8E6E-4BAD2DC52622Q28068930-451AEFE6-E8F7-49FF-A519-42C03CE3E65EQ28294829-AF038890-E23C-49AE-9109-2971713B1A8BQ28396757-D91BD8D4-999F-41E6-84EF-0C831A7C9A38Q30497854-0957EBA9-8C64-4005-B131-9C6EA5703413Q33677560-5CDAEB0C-984E-428B-8EE9-ACD349442D96Q33883973-395C7713-AFF9-4238-AF80-111E7BED3013Q33977967-1A59ECE3-9100-4027-BFDD-9DDD884463A6Q34483505-C6744362-DBCD-4AAA-976C-DE039EAF8843Q34497259-3C14D056-ED31-45D9-9ACA-4272FF6ACF8AQ34550483-AEBBEAFF-D613-4866-9AB6-5983AD70DBD6Q35039257-0A82EF08-69D0-4164-9985-F9DEA77E2742Q35194534-397F3347-5D9B-40EF-8719-F0034B3D8952Q35972218-BFCC374F-8DED-41DB-AEB8-EA6671612757Q36544972-7BCF64CA-B839-4D02-A94A-C651F5D85E82Q36548325-C3925C73-ED80-4DF2-A574-8ECF07DCD2B0Q36803952-DC129B74-3420-4C4C-AA39-61108FA12E34Q37198678-7CBE6CE6-17C0-43C2-AD2B-6D2DE05C4BB0Q37331135-7813B457-6BDE-47F4-A67C-CFA250B3DE75Q37333260-1CCC95F7-1F86-4470-9A82-28FA400C8A2DQ37395128-1FD37058-DE0B-437D-A465-FC558EB2088CQ38003479-5C724BFA-95BA-4D31-8C59-B7E76EC9E311Q38109860-CFD941D0-FDE7-41E0-AF99-0B9532ACB0EBQ39189289-71A77E1E-5951-4910-A2FA-84DE946BF91AQ40312343-8544C3E2-BF4A-4407-870F-A8A1F390B559Q42676125-A3589F9B-F0DC-46FF-AD1A-7E6BF27ECECDQ43734570-038813DA-05E9-4768-8120-5B137405CA37Q43836988-6C4F4E39-0D74-438E-B378-07F859F80E8BQ43904331-A449ED52-14B2-4DAA-8A4C-1B48D54DD9A6Q43933944-1E686C19-1FEA-4034-AF40-6FC972283BC3Q44335299-56025507-C477-4428-8633-A6F6F3BAA227Q44571948-ED990F0E-A6D2-4733-ABC0-EEAB5857772AQ47657960-19EE0AB0-6480-438A-BA4B-440CCB6F9DF9Q51428957-A0AE3851-DED3-4B98-AC70-B1EC2B35024F
P2860
Pharmacogenetics in pediatrics. Implications for practice.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacogenetics in pediatrics. Implications for practice.
@en
type
label
Pharmacogenetics in pediatrics. Implications for practice.
@en
prefLabel
Pharmacogenetics in pediatrics. Implications for practice.
@en
P1476
Pharmacogenetics in pediatrics. Implications for practice.
@en
P2093
P356
10.1016/S0031-3955(05)70463-6
P577
1997-02-01T00:00:00Z